Rockefeller Capital Management
MBRX icon

Rockefeller Capital Management’s Moleculin Biotech MBRX Stock Holding History

Rockefeller Capital Management’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.1K Buy
4,421
+4,203
+1,928% +$13.9K ﹤0.01% 3990
2025
Q4 		$722 Sell
218
-362
-62% -$3.37K ﹤0.01% 4492
2025
Q3 		$7.69K Buy
+580
New +$7.83K ﹤0.01% 3743
2023
Q1 		– Sell
-5
Closed -$1K – 3108
2022
Q4 		$1K Hold
5
– – ﹤0.01% 3711
2022
Q3 		$1K Hold
5
– – ﹤0.01% 3746
2022
Q2 		$2K Sell
5
-2
-29% -$1.16K ﹤0.01% 3804
2022
Q1 		$4K Hold
7
– – ﹤0.01% 3424
2021
Q4 		$5K Hold
7
– – ﹤0.01% 3278
2021
Q3 		$8K Sell
7
-1
-13% -$1.17K ﹤0.01% 2998
2021
Q2 		$10K Hold
8
– – ﹤0.01% 2778
2021
Q1 		$12K Buy
+8
New +$14.7K ﹤0.01% 2514
2019
Q4 		– Sell
-1
Closed -$3K – 2144
2019
Q3 		$3K Buy
+1
New +$2.58K ﹤0.01% 1731

Other funds holding MBRX

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EI
EFG International Zurich $4.67B AUM
PWPS
Pinnacle Wealth Planning Services Mansfield, Ohio $968M AUM 19.1% 1-Year Est. Return

Rockefeller Capital Management's MBRX Position: Q1 2026 in Review

Rockefeller Capital Management increased its Moleculin Biotech (MBRX) stake by 1,928% in Q1 2026, buying an estimated $13.9K and bringing the position to 4,421 shares worth $10.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3990.

Rockefeller Capital Management first reported a position in MBRX in Q3 2019 and has held it in 12 quarters since. The position peaked at $12K in Q1 2021. 20 funds tracked by Wall St. Rank hold MBRX as of Q1 2026.

  • Rockefeller Capital Management held 4,421 shares of Moleculin Biotech worth $10.1K as of Q1 2026.
  • Rockefeller Capital Management bought 4,203 Moleculin Biotech shares in Q1 2026, an estimated $13.9K.
  • Moleculin Biotech made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q1 2026, its #3990 holding.
  • Rockefeller Capital Management first reported a position in Moleculin Biotech in Q3 2019 and has held it in 12 quarters since.
  • Rockefeller Capital Management's Moleculin Biotech position peaked at $12K in Q1 2021.
  • 20 funds tracked by Wall St. Rank held Moleculin Biotech as of Q1 2026.

Based on Rockefeller Capital Management's 13F filing for Q1 2026, filed 14 May 2026.